Managing Depressive Symptoms in ADPKD: testing Digital Neurotherapy and Capacity Coaching

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional study explores whether digital neurotherapy or capacity coaching can reduce depressive symptoms and pain reports in adults with autosomal dominant polycystic kidney disease who are pre-dialysis. Participants will be assigned to receive Mayo Clinic–approved education, digital neuropathy support, or capacity coaching, with outcomes compared to an education-only control. Eligibility requires a confirmed ADPKD diagnosis, CKD stages 1–5 with preserved eGFR above 10, depression symptoms, and English proficiency. Exclusions include suicidal ideation, significant cognitive impairment, lack of internet access, and imminent dialysis or transplant.

Why it matters

Who can join: the full rules

Inclusion criteria:

* Confirmed clinical diagnosis of ADPKD using Pei-Ravine criteria
* Pre-End Stage Kidney Disease, with Stage 1-5 CKD (eGFR \>10 ml/min/1.73m2, with no anticipated dialysis or transplant within 12 months)
* Clinical or self-diagnosis of depression
* English-language fluency

Exclusion criteria:

* Suicidal ideation/unstable mental illness of any kind
* Lack of access/ability to use internet-based programs
* eGFR \<10 ml/min/1.73m2
* Anticipated dialysis or transplant within 6 months
* Prior chronic dialysis
* Prior organ (liver or kidney) transplant
* Lack of English language fluency
* Significant cognitive impairment (Mini Mental Status Exam (MMSE))

Where it's running

• Mayo Clinic
  Rochester, Minnesota, United States Recruiting

Study contacts

• Principal investigator: Neera Dahl, MD, PhD — Mayo Clinic
• Study coordinator: Ryan Helland, CCRP
• Email: RSTTEMPORESGROUP@mayo.edu
• Phone: 507-422-3998

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• AZD1613 safety and how the body handles it in adults with ADPKD

  We will test whether AZD1613 given under the skin or into a vein is safe and how the body processes it in adults with ADPKD who have eGFR between 45 and 90 mL/min/1.73m2.

  Recruiting at 10 sites Phase 1 AstraZeneca · Birmingham, Alabama and 14 other locations · NCT07228364

• Intravenous ABBV-CLS-628 for adults with autosomal dominant polycystic kidney disease

  This trial will test whether intravenous ABBV-CLS-628 given every 4 weeks is safe and helps adults with ADPKD.

  Recruiting at 72 sites Phase 2 Calico Life Sciences LLC · Birmingham, Alabama and 90 other locations · NCT06902558

• National Registry for Rare Kidney Diseases

  This study is collecting health information from people with rare kidney diseases to help improve treatments and create better care guidelines.

  Recruiting UK Kidney Association · Bristol, South West · NCT06065852

• Using Metformin to Slow Kidney Decline in Polycystic Kidney Disease

  This study is testing if metformin can help slow down kidney problems in adults with early-stage Polycystic Kidney Disease.

  Recruiting at 24 sites Phase 3 The University of Queensland · Gosford, New South Wales and 48 other locations · NCT04939935

• Evaluating biomarkers in early autosomal dominant polycystic kidney disease

  This study is trying to see if certain biomarkers can help understand how severe early autosomal dominant polycystic kidney disease is for young patients aged 15 to 40.

  Recruiting Mayo Clinic · Rochester, Minnesota · NCT04630613

• Understanding oxidative stress in patients with Autosomal Dominant Polycystic Kidney Disease

  This study is testing how oxidative stress affects young adults with Autosomal Dominant Polycystic Kidney Disease to find better ways to treat the condition.

  Recruiting Mayo Clinic · Rochester, Minnesota · NCT04344769

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.